Madrigal Pharmaceuticals, Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 filing; quarterly figures below are unaudited. Madrigal is a clinical-stage biopharmaceutical company with no product sales, focused principally on resmetirom for NASH.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $184.8 million | $72.3 million |
| General and administrative expense | $21.9 million | $22.6 million |
| Operating loss | $206.7 million | $95.0 million |
| Net loss | $202.2 million | $83.9 million |
| Basic and diluted loss per share | $13.09 | $5.45 |
| Net cash used in operating activities | $157.6 million | $41.6 million |
| Cash, cash equivalents and marketable securities at year-end | $284.1 million | $439.0 million |
| Total liabilities at year-end | $47.0 million | $25.5 million |
Q4 2020: Revenue was $0; operating expenses were $59.6 million and net loss was $59.1 million, or $3.82 per share. Q4 2019 net loss was $27.7 million, or $1.80 per share. The company reported no product gross margin; operating margins are not meaningful given the absence of revenue.
Year-end liabilities were primarily accrued expenses ($45.2 million), with lease liabilities of approximately $0.8 million. The filing reports no off-balance-sheet arrangements and no material borrowings. Operating cash use increased mainly with expanded clinical-trial activity. Investing cash inflows largely reflected purchases, sales and maturities of marketable securities, rather than operating proceeds.
Material changes versus prior year
- R&D expense rose 156% to $184.8 million, principally from Phase 3 trial activity, manufacturing to support trials and potential commercialization, and increased staffing.
- Net loss widened by $118.3 million; lower interest income ($4.3 million versus $11.0 million) also contributed to the year-over-year change.
- Cash, cash equivalents and marketable securities fell by $154.9 million, reflecting operating cash consumption, partly offset by financing and portfolio activity.
- Operating cash use increased to $157.6 million from $41.6 million. The company received $5.1 million of financing cash, including ATM sales and option exercises.
Business, outlook and key risks
- Lead program: Resmetirom, an oral, liver-directed thyroid hormone receptor beta agonist, remained investigational and had no regulatory approval. The FDA granted it Fast Track designation for NASH in 2019.
- Clinical programs: MAESTRO-NASH Phase 3 was ongoing, with enrollment incomplete at year-end. It is designed to assess NASH resolution and fibrosis outcomes, with a potential accelerated-approval filing based on week-52 biopsy results. MAESTRO-NAFLD-1 completed enrollment of its double-blind, placebo-controlled arms in October 2020, with approximately 1,200 participants enrolled overall.
- Prior Phase 2 findings: The filing describes positive 2018 NASH results, including reduced liver fat and favorable biopsy and lipid measures. These earlier findings are not Phase 3 results and do not establish approval or commercial efficacy.
- Management outlook: Management expected R&D spending to increase as development advanced and stated that year-end liquidity was expected to fund operations for more than one year from issuance of the financial statements. The company anticipated continued losses and said longer-term funding would be needed; future financing may be unavailable or dilutive.
- COVID-19: The company reported no material adverse effect on 2020 operating results, MAESTRO-NAFLD-1 or liquidity. It nevertheless cited trial and operational risks, including site constraints and slower MAESTRO-NASH screening and enrollment.
- Other risks and commitments: Outcomes, timing and safety of Phase 3 trials; regulatory review and reliance on surrogate endpoints; competition; reimbursement and commercialization readiness; dependence on third-party manufacturers and research providers; and intellectual-property rights under the Roche license. Remaining Roche regulatory milestones totaled $8 million, plus single-digit royalties on future net sales.
- Financing and dilution: A $200 million ATM program was established in November 2020. By year-end, 39,607 shares had generated approximately $4.4 million in net proceeds. A subsequent-event disclosure reports approximately $66.5 million in net ATM proceeds through February 24, 2021, with about $127.3 million remaining available under the program.
Investor verification points
- Track MAESTRO-NASH enrollment, trial milestones, endpoint results and any regulatory guidance; distinguish prospective plans from reported trial outcomes.
- Reconcile cash burn and liquidity runway against rising trial and manufacturing costs, and monitor use of the ATM and resulting dilution.
- Review accrued clinical-trial costs: $31.6 million in CRO accruals at year-end, estimated using management judgment and identified as a critical audit matter.
- Assess resmetirom’s long-term safety, likelihood of meeting Phase 3 endpoints, potential post-approval study obligations, and competitive and reimbursement conditions.
- Check the Roche license terms, future milestone obligations, royalty provisions and patent protections; confirm the latest share count and outstanding equity-linked securities.
The auditor issued an unqualified opinion on the financial statements and stated that internal control over financial reporting was effective as of December 31, 2020.